Table 2. Association of uUMOD with kidney outcomes and mortality in older community-living adults.
| uUMOD quartiles | Linear model | |||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | Per SD increase = 27.1 µg/mL | p-value | |
| ≤ 15.80 | 15.81 – 25.86 | 25.87 – 40.27 | > 40.27 | |||
| ≥ 30 eGFR decline (case-cohort design) | ||||||
| N | 126 | 125 | 126 | 124 | 501 | |
| Events | 26 | 10 | 23 | 22 | 81 | |
| Incidence rate (%/yr)* | 3.22 | 1.2 | 2.38 | 2.49 | 2.32 | |
| Model 1** | 1.00 (ref) | 0.74 (0.48, 1.13) | 0.64 (0.41, 0.99) | 0.90 (0.58, 1.40) | 1.02 (0.86, 1.20) | 0.864 |
| Model 2† | 1.00 (ref) | 0.80 (0.52, 1.23) | 0.78 (0.50, 1.21) | 0.94 (0.60, 1.49) | 1.03 (0.86, 1.23) | 0.792 |
| Model 3‡ | 1.00 (ref) | 0.82 (0.53, 1.26) | 0.93 (0.60, 1.44) | 1.10 (0.69, 1.75) | 1.08 (0.90, 1.29) | 0.418 |
| Incident CKD (subcohort only) | ||||||
| N | 126 | 125 | 126 | 124 | 501 | |
| Events | 46 | 31 | 33 | 22 | 132 | |
| Incidence rate (%/yr) | 5.70 | 3.72 | 3.41 | 2.49 | 3.78 | |
| Model 1** | 1.00 (ref) | 0.62 (0.39, 0.99) | 0.50 (0.31, 0.80) | 0.40 (0.23, 0.69) | 0.75 (0.58, 0.97) | 0.029 |
| Model 2† | 1.00 (ref) | 0.69 (0.43, 1.11) | 0.59 (0.36, 0.97) | 0.44 (0.25, 0.76) | 0.77 (0.61, 0.99) | 0.037 |
| Model 3‡ | 1.00 (ref) | 0.68 (0.41, 1.11) | 0.63 (0.38, 1.05) | 0.47 (0.27, 0.82) | 0.79 (0.52, 1.01) | 0.055 |
| Rapid kidney function decline (subcohort only) | ||||||
| N | 88 | 103 | 104 | 94 | 389 | |
| Events | 28 | 15 | 32 | 16 | 91 | |
| Incidence rate (%/yr) | 4.79 | 2.17 | 3.91 | 2.40 | 3.3 | |
| Model 1** | 1.00 (ref) | 0.35 (0.17, 0.69) | 0.67 (0.39, 1.16) | 0.43 (0.22, 0.83) | 0.73 (0.52, 1.02) | 0.064 |
| Model 2† | 1.00 (ref) | 0.37 (0.18, 0.75) | 0.66 (0.38, 1.16) | 0.50 (0.25, 0.98) | 0.77 (0.55, 1.07) | 0.123 |
| Model 3‡ | 1.00 (ref) | 0.35 (0.16, 0.73) | 0.60 (0.33, 1.10) | 0.49 (0.24, 0.99) | 0.76 (0.55, 1.06) | 0.109 |
| All-cause mortality (subcohort only) | ||||||
| N | 126 | 125 | 126 | 125 | 502 | |
| Events | 68 | 68 | 55 | 57 | 248 | |
| Incidence rate (%/yr) | 5.40 | 5.23 | 3.85 | 4.28 | 4.66 | |
| Model 1** | 1.00 (ref) | 0.87 (0.61, 1.24) | 0.57 (0.39, 0.83) | 0.63 (0.43, 0.92) | 0.81 (0.68, 0.96) | 0.017 |
| Model 2† | 1.00 (ref) | 0.95 (0.67, 1.36) | 0.65 (0.44, 0.94) | 0.70 (0.48, 1.02) | 0.84 (0.71, 0.99) | 0.040 |
| Model 3‡ | 1.00 (ref) | 1.09 (0.75, 1.59) | 0.74 (0.50, 1.10) | 0.79 (0.53, 1.17) | 0.86 (0.73, 1.02) | 0.084 |
*Incidence rate for > 30 eGFR decline is calculated from the random subcohort only. **Adjusted for age, gender, race, education, and site. †Additionally adjusted for estimated glomerular filtration rate and urine albumin-creatinine ratio. ‡Additionally adjusted for diabetes, systolic blood pressure, antihypertensive medications, smoking status, body mass index, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, statin use, and C-reactive protein.